The portion of the brainstem between the midbrain and the medulla oblongata.
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. Diffuse high-grade lesions in children, although rare (occurring in approximately one in 100,000 individuals) 1 , retain the same dismal prognosis as those that arise in adults (median survival 12-15 months), particularly for those arising in the pons (median survival of 9-12 months) 2 . In addition to the supratentorial locations in which the vast majority of adult tumours occur, children frequently present with histologically similar World Health Organization (WHO) grade IV glioblastoma in midline structures, including the thalamus (13%) 3 and spinal cord (3%) 4 , as well as the cerebellum (5%) 5 (FIG. 1) . A diverse spectrum of grade III lesions may also occur
. This Review will focus on the diffuse HGGs of childhood, which predominantly encompass glioblastoma (grade IV), as well as anaplastic astrocytoma (grade III).
Approximately one-half of all malignant gliomas in children arise in the brainstem, most frequently within the ventral pons as diffuse intrinsic pontine glioma (DIPG) 6 . 'Typical' DIPGs represent one of the most severe challenges in neuro-oncology, as the anatomical location precludes surgical resection and makes adequate drug delivery challenging 6 . Radiotherapy provides only a transitory response and the use of chemotherapy is ineffective 2, 7 . Research has been historically hampered by the lack of available material for biological research; reintroduction of a safe stereotactic procedure, as well as engagement with families to access samples at autopsy, have helped to address this challenge [8] [9] [10] 
.
DIPGs occur almost exclusively in children, with a peak in incidence from ages 6-8 years, coinciding with an expansion of a nestin-and oligodendrocyte transcription factor 2-expressing (Nestin + OLIG2 + ) neural precursor-like cell population in the ventral pons, which has been proposed to be the possible cell-of-origin 11 . By contrast, supratentorial tumours predominantly occur during adolescence (median age 11-12 years) 3, 5 , although they may also be found in other age groups, including infants (<3 years). Tumours in the infant age group seem to respond considerably better to chemotherapeutic regimens and have improved clinical outcomes 12 , hinting at a distinct biology. Clinical trials in paediatric HGG historically relied on biological hypotheses and preclinical data derived from studies of adult glioblastoma. HGGs represent a spectrum of diseases, with shared histopatho logical features among childhood and adult tumours 13 . In addition, the same gene expression subgroups that were initially identified in adult HGG are easily identified in paediatric HGGs, which further reveals the clear relationship among these disease groups [14] [15] [16] [17] . However, recent molecular profiling data, principally generated through collaborative studies, have definitively shown that childhood tumours are biologically distinct from their adult counterparts and strongly suggest that there are unique molecular processes driving the evolution of HGGs in children. Although HGGs in both adults and children were recently reviewed 18 , in light of several new studies and the special nature of the paediatric disease, this Review is focused on childhood HGG and will discuss exciting new insights into the molecular pathogenesis of this disease, illuminating distinct genetic mutations among subgroups of childhood HGG arising in particular anatomical regions, as well as among different age groups.
Genetic complexity of paediatric HGGs
Most paediatric HGGs have complex genomic signatures, with significant copy number alterations (CNAs), single nucleotide variants (SNVs) and structural variants 15, 16, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Although the number of non-synonymous mutations is lower than in common adult cancers, including adult glioblastoma, HGGs have a greater mutation burden than several other paediatric cancers [19] [20] [21] [22] (FIG. 2) . Structural variants ranging from simple rearrangements to extensive and complicated abnormalities caused by chromothripsis are common in paediatric HGG [19] [20] [21] [22] , with approximately 50% of all cases showing expression of fusion genes as detected by RNA sequencing (RNA-seq) 22 .
Although most paediatric HGGs show an average of five to six large-scale CNAs, as well as focal deletions or amplifications, there is a subset of cases across the paediatric age group with very stable genomes and few to no detectable CNAs 16, 24 . At least some of these cases are hypermutator tumours that arise in the context of germline mutations in mismatch repair genes. In these cases, the number of somatic SNVs may be more than 100-fold higher than that found in 95% of paediatric HGGs 22 (FIG. 2) . Germline mutations in the TP53 and neurofibromin 1 (NF1) tumour suppressors are known to cause inherited predisposition to HGGs 29 , and a subset of paediatric HGGs arise in this context of increased genetic risk. However, the overall mutation burden and specific cooperating mutations in these HGGs are similar to those seen in sporadic cases 22 . The genomic landscape of non-brainstem HGGs (NBS-HGGs) arising in children less than three years old is strikingly different, with significantly lower mutation burdens, in some cases showing only two non-silent mutations across the entire genome 22 (FIG. 2) .
Interestingly, NBS-HGGs in this age group are also clinically distinct, as they are associated with a significantly greater survival compared with NBS-HGGs in older children 12 . In a small cohort, 40% (four of ten patients) of NBS-HGGs arising in this <3-year-old age group carried chimeric oncogenes involving fusions of 5′ regions from different genes to sequences encoding the kinase domain from neurotrophic tyrosine kinase receptor type 1 (NTRK1), NTRK2 or NTRK3. Consistent with the extremely low number of additional mutations in infant NBS-HGGs, two NTRK fusions that were tested (that is, tropomyosin 3 (TPM3)-NTRK1 and BTBD1-NTRK3) showed strong oncogenic activity, transforming Tp53-null astrocytes to drive rapid HGG formation in vivo 22 . Two of the NTRK fusion genes identified in paediatric HGG, the ETS variant 6 (ETV6)-NTRK3 fusion and the TPM3-NTRK1 fusion, were previously identified in other tumours. The ETV6-NTRK3 fusion was identified in congenital fibrosarcomas and mesoblastic nephromas, leukaemia, and adult secretory breast cancer [30] [31] [32] [33] , whereas the TPM3-NTRK1 fusions are recurrent in papillary thyroid carcinoma 34 . In brain tumours, NTRK fusions were not uniquely associated with infant NBS-HGG. They were also found at lower frequency in DIPG, NBS-HGG from older patients, in paediatric low-grade glioma in the context of very few additional mutations, and in adult glioblastoma, where they were present with multiple additional mutations [35] [36] [37] . Thus, the genomic complexity of paediatric HGG spans a wide range, with infant NBS-HGG and HGGs from patients with inherited mutations in mismatch repair genes at the extreme opposite ends of the spectrum (FIG. 2) . The paucity of mutations in infant tumours suggests that therapeutic targeting of NTRK fusions may be highly effective in the absence of a large number of other mutations. However, the genomic complexity of most HGGs, including DIPGs, indicates that multiple genetic mechanisms generate numerous mutations that provide the tumour with diverse potential pathways to therapeutic resistance. HGGs in children frequently arise as diffuse intrinsic pontine glioma (DIPG) in the pons, or in other midline structures such as the thalamus or less frequently in the cerebellum or spinal cord. Childhood HGGs can also arise in the cerebral cortex, the region in which most HGGs in adults originate. Mutation frequencies indicate differences in selective pressures between different regions of the developing brain. For example, histone H3.3 G34R or G34V mutations and BRAF-V600E mutations are predominantly found in cortical tumours, histone H3 K27M mutations are found in all midline locations, with the highest frequency in DIPG, activin receptor type 1 (ACVR1) mutations are restricted to DIPG, and fibroblast growth factor receptor 1 (FGFR1) mutations are found in thalamic HGGs.
Mutations in canonical cancer pathways Paediatric diffuse HGGs show frequent genetic alterations in the same canonical cancer pathways that are deregulated by mutation in almost all adult glioblastomas -the receptor tyrosine kinase (RTK)-RAS-PI3K pathway, the TP53 pathway and the RB pathway 38,39 -however, the specific effectors that are most frequently targeted by mutation vary between childhood and adult tumours 18 (FIG. 3) . Mutations of the catalytic and regulatory subunits of PI3K (which are encoded by PIK3CA and PIK3R1, respectively) are found in both paediatric and adult HGG, whereas biallelic inactivation of the PTEN tumour suppressor is common in adult but rare in childhood HGGs. The 'hotspot' BRAF V600E activating mutation is found in approximately 10% of paediatric cortical HGGs, in lower frequencies in thalamic HGGs, and is not detected in DIPG. BRAF V600E mutations were also found in more than 70% of pleomorphic xanthoastrocytomas and approximately 50% of anaplastic gangliogliomas, both of which are rare tumours found in both children and adults 22, 23, [40] [41] [42] [43] [44] . Thus, mutant BRAF may be a useful therapeutic target in a subset of childhood HGGs. Platelet-derived growth factor receptor-α (PDGFRA) is the most commonly mutated RTK in paediatric HGG, and epidermal growth factor receptor (EGFR) mutations, which predominate in adult glioblastoma, are relatively rare 15, 16, [22] [23] [24] [25] [26] [27] [28] 45 . Approximately 30% of paediatric HGGs across all brain regions carry focal amplification and/or mutation of PDGFRA, involving a unique spectrum of mutations compared to those found in adult glioblastoma 23, 25, 45 . Amplification of MET and insulin-like growth factor 1 receptor (IGF1R) are also found in paediatric HGG 15, 16, [24] [25] [26] . Activating mutations in fibroblast growth factor receptor 1 (FGFR1) were identified in thalamic HGGs, but not in paediatric HGGs from the cortex or brainstem 20, 22 . Although RTKs are actionable therapeutic targets with approved drugs to inhibit their activity, a survey of DIPGs showed that RTK amplification was extremely heterogeneous within tumours 15 , as has been shown in adult glioblastoma [46] [47] [48] . This genetic heterogeneity is likely to pose a very substantial challenge to the design of personalized therapy to counteract specific mutations, as there may already be pre-existing resistant populations of tumour cells that lack the drug target.
TP53 mutations are found in approximately 55% of paediatric HGGs [19] [20] [21] [22] [23] . There are also mutually exclusive mutations in 9-23% of DIPGs and midline HGGs in the TP53 target gene PPM1D 21, 22 , which has a role downstream of p53 in the DNA damage response. The RB pathway is targeted at a considerably lower frequency in paediatric HGGs than in adults and shows striking differences in the genes involved based on tumour location. Homozygous deletions of cyclin-dependent kinase inhibitor 2A (CDKN2A) are found in approximately 25% of NBS-HGGs but are extremely rare in DIPGs. Focal amplification of CDK4, CDK6 or cyclin D1 (CCND1), CCND2, or CCND3 (the components of the . Grade III disease is distinguished from lower grade tumours on the basis of architectural and cytological features, pleomorphism and mitotic activity. The subclassification of grade III tumours is based on the morphological similarities of the predominant tumour cell population to normal glial cell counterparts. The most common subtype is anaplastic astrocytoma, in which tumour cells resemble astrocytes, and, at much lower frequencies, anaplastic oligodendroglioma and anaplastic oligoastrocytoma, in which tumour cells resemble oligodendrocytes, or a mixture of both, respectively. It remains unclear whether these morphologies reflect the tumour cell-of-origin or variation in differentiation of a transformed glial progenitor or a more primitive neural progenitor cell. There are also several additional rare variants.
Grade IV diffuse glioma is also known as glioblastoma, which is the most malignant of the diffuse astrocytomas. They share the high mitotic activity, nuclear atypia and cellular pleomorphism of grade III tumours, but they are further distinguished by the additional features of microvascular proliferation and/or regions of necrosis.
Diffuse intrinsic pontine gliomas (DIPGs) predominantly arise in the ventral pons and occur almost exclusively in children. Most samples that are evaluated at autopsy are classified as glioblastoma (grade IV), although biopsy studies have shown that some DIPGs may appear to be low grade (grade II) or grade III, at least in the small regions evaluated 93, 94 . DIPGs represent an entity that is distinct from true low-grade gliomas of the brainstem (WHO grade I), which often have a pronounced dorsal exophytic component and frequently harbour BRAF-KIAA1549 gene fusions, which are also a hallmark of low-grade pilocytic astrocytomas 15 . While most adult glioblastomas, termed primary glioblastoma, also seem to arise as de novo lesions, progression of grade II to grade III gliomas is common, and a subset of adult glioblastomas termed secondary glioblastoma arises through further malignant transformation of lower grade tumours. These progressive lesions are strongly associated with the presence of isocitrate dehydrogenase 1 (IDH1) mutations, and probably represent a subset of high-grade gliomas (HGGs) occurring in older adolescents 18 . Because grade II and grade III gliomas in adults represent a continuum of progressive disease that shares several mutations, these tumours are often grouped together in analyses of adult glioma genetics. By contrast, grade III diffuse gliomas of childhood, like glioblastomas, generally occur without clinical or histological evidence of malignant transformation of a lower grade precursor lesion, and progression of low-grade to high-grade disease is rare 59 . As detailed in this Review, paediatric grade III diffuse gliomas are more similar to glioblastoma than to grade II tumours in terms of clinical behaviour, gene expression signatures and genetic abnormalities. Therefore, in this Review, we have grouped grade III and grade IV paediatric diffuse gliomas together for analysis and discussion of paediatric diffuse HGG.
cyclin-CDK complex that phosphorylate RB at the G1 checkpoint) are found in paediatric HGGs from all brain regions 15, 24, 26 . Although loss of chromosome 13q is found in approximately one-third of paediatric HGGs regardless of location, biallelic loss-of-function mutations in RB are extremely rare [19] [20] [21] [22] [23] . Therefore, both NBS-HGGs and DIPGs may be effectively targeted by CDK4 and/or CDK6 inhibitors. Indeed, preclinical studies with these agents showed some efficacy in a mouse model of DIPG 49 . Thus, therapeutic approaches designed to counteract aberrant regulation of pathways that are of central importance in most common cancer types are also highly relevant to childhood HGG. However, there are oncogenic mutations that are unique to paediatric HGG that must also be considered.
Connecting chromatin regulation and cancer
Genome-wide sequencing efforts of paediatric glioblastoma and DIPG identified recurrent and hotspot mutations in H3 histone, family 3A (H3F3A) and histone cluster 1, H3b (HIST1H3B), which encode the histone H3 variants H3.3 and H3.1 respectively 23, 50 . This unexpected finding was the first example of a human disease driven by direct mutation of histones 51, 52 . Moreover, as these mutations are not found in adult HGG, these data provided compelling evidence that distinct molecular processes underlie paediatric and adult HGG.
Histone H3 isoforms H3.1 and H3.2 are synthesized during the S phase of the cell cycle to package newly replicated DNA, whereas H3.3 is synthesized throughout the cell cycle and used to replace histones that are lost during processes that disrupt nucleosomes 53,54 . Histone H3.1 is encoded by ten genes that encode identical proteins, although, to date, almost all histone H3.1 mutations are found in HIST1H3B, with two rare examples of HIST1H3C K27M in DIPG 19, 20 . HIST1H3B-mutant DIPG furthermore seems to represent a distinct subgroup, with a younger age at diagnosis (4-5 years) and a longer survival time (median of 15 months), though with no improvement in eventual clinical outcome [19] [20] [21] [22] (FIG. 4) .
Histone H3 mutations occur at two residues -the lysine at position 27 (lysine to methionine (K27M)) and the glycine at position 34 (glycine to arginine (G34R) or glycine to valine (G34V)). Strikingly, the mutations have a distinct anatomical segregation, and this illustrates a previously unrecognized highly specific selection pressure that is evident in different cell types during brain development, and it provides strong evidence that the molecular pathogenesis of DIPG is significantly different from tumours arising in the cerebral hemispheres.
K27M mutations were observed in 78% of DIPGs, as well as other tumours of midline structures, including the thalamus (40%) and the spinal cord, with most of these mutations in H3F3A encoding histone H3.3, and up to 25% in histone H3.1 (REFS 19, (21) (22) (23) 50, 55, 56) .
By contrast, G34R or G34V mutations are exclusively in H3F3A and predominantly restricted to tumours of the cerebral hemispheres (15%) 17, 20, 22, 23, 50, [55] [56] [57] . The different mutations also have a distinct age of diagnosis (median 6-7 years for K27M; median 13-14 years G34R or G34V) and survival (median of 12 months for K27M; median of 24 months for G34R or G34V) 17,19-22,55,56 ,
Box 2 | Clinical sampling of diffuse intrinsic pontine glioma
The diagnosis of diffuse intrinsic pontine glioma (DIPG) relies upon radiological and clinical parameters, and not on the basis of histopathological features, because resection is not a viable option, owing to its location in the brainstem. Indeed, in 1993, an influential report from the Children's Cancer Group recommended against exposing patients with DIPG to risks from surgical procedures, and this resulted in a lack of tissue for research 95 .
The opening of rapid autopsy protocols
To expand the altruistic donation of tumour samples, groups at St Jude Children's Research Hospital in Memphis, Tennessee, USA, and the Hospital for Sick Children in Toronto, Ontario, Canada, began to offer the possibility of enrolling in a rapid autopsy protocol for the collection of tumour tissue post-mortem 9, 10 . Such protocols provided sufficient quantities of undegraded DNA and RNA for molecular profiling 15, 27 and genome sequencing studies 19, 22, 50 , which have revolutionized our understanding of the biology of the disease. With appropriate clinical and bereavement counselling, participating in such a programme has proven to be an overwhelmingly affirming experience for these families and has encouraged the expansion of such an approach worldwide 96 . It will remain an important source of material for the study of DIPG, particularly as it facilitates whole-brain studies and provides a unique opportunity for direct assessment of intratumoural heterogeneity through multi-region sampling approaches.
Reintroduction of safe biopsy procedures
In the past decade, neurosurgical teams (as part of a multidisciplinary paediatric neuro-oncology group in Paris, France) started to offer image-guided stereotactic biopsies of DIPG, with a key endpoint being sample collection for future biological study. With nearly 200 patients undergoing these procedures, there have been no surgery-related deaths and low, transient morbidity rates of less than 4% (REF. 8 ), and these samples give a sufficient quantity and quality of tumour cell material for histological and molecular pathology analysis 25, 97 , as well as comprehensive genome sequencing 20, 21 . The sampling of tumours prior to the start of radiotherapy importantly allows for these experiments to be carried out in a treatment-naive context, without the possibility of confounding radiation-induced mutations. At a multidisciplinary consensus conference in 2011, the use of biopsy was formally recommended to ascertain biological characteristics to enhance the understanding and targeting of treatments, especially in clinical trials 98 . As novel subgroup-specific drug targets are identified, this will become a crucially important component of finally improving outcome in this most challenging of paediatric brain tumours. Nature Reviews | Cancer 10,000
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in part reflecting the onset and survival associated with HGGs from cortical versus brainstem and midline locations. Importantly, G34R or G34V mutations are found not only in children but also in older patients with HGG who are beyond the paediatric age groupextending up to patients approximately 30-40 years of age -indicating that molecular diagnostics spanning traditional paediatric and adult neuro-oncology services will be vital in the common management of these patients as one disease entity 56 . Similarly, although rare in the adult population, 88% of thalamic tumours that arise in patients between the ages of 21 and 49 years old have K27M mutations 58 . Paediatric HGGs generally seem to arise as de novo lesions without evidence of lower grade precursor disease 59 ; therefore, it is not clear whether histone H3 mutations arise as early or late events in tumorigenesis. However, the mutations clearly provide a strong selective advantage, because in most tumours, next-generation sequencing shows that the H3F3A mutation seems to be heterozygous in 100% of cells, indicating clonal selection without substantial intratumoural heterogeneity [19] [20] [21] [22] [23] 50, 55 . Furthermore, histone H3 K27M mutations have been identified at similarly high frequencies in both untreated biopsies and autopsy specimens after exposure to radiotherapy and other therapies, as well as in histological low-grade and high-grade regions of DIPGs [19] [20] [21] [22] 50, 55 .
Structural consequences of histone mutations in paediatric HGG. Both of the amino acids that are targeted by recurrent mutations reside in the unstructured amino-terminal tail of histone H3. Post-translational modification of histone tails represents a key regulatory mechanism by which cells exert fine control of gene transcription. These processes seem to be particularly important in the spatiotemporal control of gene expression during normal development 60 , stem cell maintenance 61 and differentiation 62 . The regulation of histone tails is generated through diverse combinations of different post-translational modifications, including methylation, acetylation, or ubiquitylation of lysine residues, as well as phosphorylation of serine or threonine residues and methylation of arginine residues. The enzymes that catalyse the addition or removal of these moieties are known as chromatin 'writers' or 'erasers' , respectively. The resulting complex patterns create a histone code in which effector proteins (also known as 'readers') are recruited to the chromatin by specific binding to particular histone modifications, resulting in localization of functional complexes that affect transcriptional regulation 63 . Chromatin compaction is also affected by post-translational modifications of histone tails, as well as through the action of other chromatin remodelling proteins, which may function to change nucleosome position and conformational structure. All of these different levels of chromatin regulation are increasingly understood to have crucial roles in oncogenesis, with numerous recurrent mutations observed in chromatin writers, erasers, readers and remodellers in a diverse series of human cancers 64 . Owing to the ubiquity of cellular histone expression and the high degree of redundancy of genes encoding these proteins, it was assumed that these genes were unlikely to be mutational targets themselves 52 . Remarkably, HGGs in children shifted this paradigm.
Functional consequences of histone mutations in paediatric HGG. The unique functional consequences that are associated with each of the mutations observed in . Boxes represent interquartile range. Whiskers represent a range of maximum and minimum points no more than 1.5 quartiles. Outliers are marked by the dashes. Infant HGGs (red) have the lowest number of somatic mutations per sample other than paediatric low-grade glioma (LGG), with a median of 2. Paediatric HGG (pink) and diffuse intrinsic pontine glioma (DIPG; purple) have very similar profiles, with a median of 15 non-synonymous coding mutations per sample for both -considerably lower than for adult glioblastoma (61 mutations per sample; P <0.001 for both paediatric HGG and DIPG; Mann-Whitney U test). There was no significant difference between pre-treatment DIPG samples taken at biopsy and post-treatment samples at autopsy. Untreated paediatric HGG that was classed as 'hypermutator' (green) harboured the highest mutational burden of all, with a median of 6,810 (range 262-18,369) non-synonymous coding mutations per sample. AML, acute myeloid leukaemia; CLL, chronic lymphocytic leukaemia. Nature Reviews | Cancer paediatric HGG are only just beginning to be elucidated. The K27M mutation occurs at a specific lysine methylation or acetylation site and as such was immediately presumed to have severe consequences for the control of gene expression that is associated with this key residue. Trimethylated K27 (K27me3) interacts with Polycomb repressive complex 2 (PRC2) to repress transcription of target genes -a process that is seemingly key in the regulation and development of stem cells 65 . K27M (and to a lesser extent K27I) represents the only amino acid substitution at this residue that can ablate this trimethylation 66 , suggestive of why this specific mutation is selected for in paediatric HGG. What is more extraordinary is that although the mutant histone seems to represent only 3.6-17.6% of the total H3 pool in the cell 66 , the loss of H3K27me3 is near-absolute, indicative of a trans-dominant-negative effect across all three isoforms of the wild-type H3 protein [66] [67] [68] [69] . This has been shown to result in a generalized hypomethylation and upregulation of gene expression 68 , exemplifying the complex interactions between genetic and epigenetic mechanisms of gene transcription control. In addition, the predicted derepression of PRC2 target genes clearly occurs in K27M-mutant tumours, probably influencing diverse pro-tumorigenic processes 66, 68 . Of note, there remains a small proportion of trimethylated marks present at H3K27, which then seem to bind to distinct target genes that are not associated with wild-type cells, although further studies may be required to elucidate whether transcripts are consistently dysregulated by this mechanism 68, 69 . This differential binding of mutated H3.3 variants may be even more pronounced in cortical tumours harbouring G34R or G34V mutations. The mutated residue is not itself a known target of post-translational modification; however, it is adjacent to K36, the trimethylation of which is associated with activation of gene transcription, as well as effects on alternative splicing and DNA repair 70 . The G34R substitution has been shown to diminish trimethylation at the K36 position in vitro, although only on the mutant allele 66 . Thus, the G34 mutations do not exert the same dominant effect over the entire cellular pool of histone H3 that is observed with K27M mutations.
In a single cell line model of G34V-mutant paediatric glioblastoma, the mutant protein was found to bind at a distinct set of target genes associated with cortical development and stem cell maintenance 17 . Strikingly, the most significantly differentially bound and expressed gene was MYCN, a potent oncogene in diverse paediatric cancers that has been shown to transform neural stem cells derived from the developing cortex and to produce glioblastomas in mice 71 . This upregulation of MYCN was also seen in primary paediatric tumours with G34R or G34V mutations compared to H3F3A-wild-type tumours, with the exception of MYCN-amplified cases, which are mutually exclusive with histone mutations 17 . Although thera peutic approaches to directly target H3.3 mutations remain elusive, numerous strategies have emerged to destabilize the MYCN protein 72 . Thus, MYCN may be of immediate translational relevance in children with these tumours. It remains unclear how the glycine-to-arginine substitutions differ mechanistically compared with the glycine-to-valine substitutions. Arginine may itself be a target of post-translational modification 73 , thus hinting at key functional differences; however, a lack of G34 model systems has hampered our understanding.
Alternative histone H3 mutations were recently found in two rare childhood bone tumours. Giant-cell tumours of bone harbour G34W or G34L mutations in H3F3A in 92% of cases, indicating that different amino acid substitutions for G34 may be oncogenic in different tumour types. In addition, 95% of chondroblastomas have K36M mutations in H3F3B 74 , which encodes the histone variant H3.3. Intriguingly, the substitution of methionine for lysine results in a dominant loss of all trimethylation of K36, thus showing a similar function to the K27M mutation, with both mutations showing specificity for dominantly decreasing trimethylation of the lysine in the same position as the mutation. . PI3Kα is comprised of the p85 regulatory subunit and the p110α catalytic subunit, encoded by PIK3R1 and PIK3CA, respectively. PI3K phosphorylates the signalling lipid phosphatidylinositol 4,5-bisphosphate (PIP2) to generate PIP3, leading to subsequent activation of downstream cascades, including the serine/threonine kinase AKT. The PTEN tumour suppressor is a protein and lipid phosphatase that directly reverses the action of PI3K. Growth factor binding to RTKs can activate both RAS and PI3K through different adaptor proteins, or through direct interaction with PI3K, depending on the specific receptor. RAS is a small G protein that is activated when in the GTP-bound state. The neurofibromin 1 (NF1) tumour suppressor is a GTPase-activating protein that negatively regulates the activity of RAS. RAS participates in PI3K pathway signalling and in downstream signalling through the serine/threonine kinase BRAF to additional downstream targets in the MAPK pathway. The frequencies of mutations for the most recurrently mutated components of these pathways in paediatric HGG are indicated [19] [20] [21] [22] [23] . Some mutations show different frequencies in cortical (Cort) versus thalamic or midline HGGs or diffuse intrinsic pontine gliomas (DIPGs). Of note, PTEN and epidermal growth factor receptor (EGFR) mutations, which are frequent in adults, are not highly recurrent in childhood HGGs. FGFR1, fibroblast growth factor receptor 1; IGF1R, insulin-like growth factor 1 receptor; mut, mutated; NTRK, neurotrophic tyrosine kinase receptor; PDGFRA, Platelet-derived growth factor receptor-α; amp, amplified. 
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Ganglionic eminences
Transient structures in the embryonic telencephalon that guide tangential cell migration.
It remains to be seen whether additional tumour types harbour similar histone mutations and whether there is a specific commonality that is yet to be elucidated between bone and brain development.
Developmental origins of paediatric HGG subtypes.
Paediatric HGGs with histone H3 mutations were associated with distinct signatures of genome-wide DNA methylation 56 . These methylation signatures, as well as the marked and differential gene expression signatures associated with histone H3 mutations, also provide clues to the developmental origins of the tumours in which they are found. Comparison of gene expression signatures between DIPGs and NBS-HGGs showed a significant differential expression of transcription factors that are associated with hindbrain patterning 15 . Comparing maps of histone mutation-specific expression signatures from paediatric HGG to published data sets of human brain developmental expression signatures showed that signatures for the various paediatric HGG subtypes have distinct developmental origins, which mimics what has been described in other paediatric brain tumours, such as ependymoma 75 and medulloblastoma 76 . G34R or G34V signatures are highly enriched in the ganglionic eminences that are present in the late embryonic and early fetal stages of development and which are the regions from which cortical interneurons and a rich pool of neuroprogenitors arise 17 . By contrast, K27M signatures overlap with hindbrain developmental structures at later fetal timepoints, and probably point to a different cell of origin 17, 56 . Of note, the gene expression signatures of K27M-mutant tumours from the pons and the thalamus show strong similarities 22, 25 , which suggests that these tumours share a common origin and should be considered together clinically; supported by the dismal clinical outcome for a substantial proportion of patients with thalamic glioblastoma 3 . The anatomical distribution within the cortex of diffuse HGGs that arise during the transition from late adolescence to young adulthood also suggests a potential difference in tumour susceptibility associated with developmental context. For example, isocitrate dehydrogenase 1 (IDH1)-mutant gliomas, which are strongly associated with adult secondary glioblastomas and the lower grade diffuse gliomas from which they arise, more frequently occur within the frontal lobe, whereas the mutually exclusive population of histone H3 G34-mutant tumours is more commonly found in the other lobes of the cerebral cortex 18, 23, 56 .
Mutations in other chromatin regulators in paediatric HGG. In addition to the specific mutations in the genes encoding the histone variants, other chromatin regulators may also be targeted in paediatric HGG. The histone chaperones α-thalassaemia/mental retardation syndrome X-linked (ATRX) or death-domain associated protein (DAXX) are mutated in 15-25% of tumours, co-segregating with G34R or G34V mutations 20, 22, 23 . These proteins are involved in the loading of histone H3.3 to the heterochromatic regions at the telomeres 77 , and the concurrent H3F3A-and ATRXand/or DAXX-mutant tumours are strongly associated with a telomerase-independent alternative lengthening of telomeres phenotype in a proportion of paediatric HGGs 23 . In adults, mutations in ATRX or the telomerase reverse transcriptase (TERT) promoter are mutually exclusive and represent different mechanisms to lengthen telomeres. Although TERT promoter mutations are found in 83% of adult glioblastomas, these H3.3 K27M mutations are found in nearly two-thirds of DIPG, one-half of thalamic HGG, and other midline tumours. H3.1 K27M mutations are found in more than 20% of DIPGs and 5% of midline HGGs, and are strongly associated with younger patient age [19] [20] [21] [22] . H3.3 G34R or G34V mutations are found in 15% of paediatric HGGs and are restricted to cerebral hemispheric tumours in adolescents and young adults, and they confer differential distribution of the activating H3K36me3 mark. b | Mutations in other chromatin modifiers. Numerous 'writers' (top) and 'erasers' (bottom) of histone H3 lysine marks are mutated in paediatric HGG and DIPG, with an apparent exception of K27. Lysines in the H3 tail that are modified by trimethylation (Me marks) or acetylation (Ac) are indicated. In addition, H3 chaperones such as α-thalassaemia/mental retardation syndrome X-linked (ATRX) or death-domain associated protein (DAXX) are mutated in 15-20% of supratentorial tumours, along with various other chromatin remodellers in tumours of all locations [21] [22] [23] . ARID1B, AT-rich interactive domain-containing protein 1B; CHD, chromodomain helicase DNA-binding protein; JMJD1C, jumonji domain containing 1C; KDM, lysine-specific demethylase; MLL, mixed-lineage leukaemia protein; SMARC, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin. Nucleus P mutations are found in less than 3% of paediatric diffuse HGGs 22, 78 . In addition, the specific methyltransferase that is responsible for depositing the methyl marks at the K36 residue (that is, SETD2) is also found to be mutated in 5-15% of paediatric HGGs 20, 22, 57 . Whether this mutation confers the same phenotype as the G34 mutations is not clear; however, unlike H3F3A, these mutations are not mutually exclusive with those in IDH1 or IDH2 (REF. 57 ), which are more frequently found in clinical secondary adult (age 40-50 years) glioblastoma 79 . Strikingly, mutations in writers or erasers of all modified methylated lysines of the histone H3 tail were found, except for those that affect K27 . Thus, in paediatric HGG, disrupted regulation of K27 modification is mediated directly through mutation of histone H3.
Further non-recurrent mutations are found in a diverse range of chromatin readers or writers, such as members of myeloid and/or lymphoid leukaemia or mixed-lineage leukaemia (MLL), and lysinespecific demethylase (KDM) and chromodomain helicase DNA-binding protein (CHD) families [19] [20] [21] [22] have been found in pHGGs in common with other tumour types, including primary adult glioblastoma 80 . The complex interplay of these mutations with the mutant histones is not yet clear, nor is the most efficacious way to clinically target the histone mutations themselves. A concurrent upregulation of acetylation at K27, in association with the loss of trimethylation that occurs in K27M cells 66 , points towards the use of inhibitors of histone acetyltransferases, whereas differential loading of residual H3K27me3 may suggest a role for specific inhibitors of the histone demethylases lysine specific demethylase 6B (KDM6B; also known as JMJD3) or KDM6A (also known as UTX) 81 . Targeting the downstream consequences of these mutations, such as the upregulation of MYCN in G34R or G34V tumours, or specific K27M targets, such as CDK6 and PDGFRα 68, 69 that are also dysregulated by gene amplification 16, 24, 26, 27 , may prove to be therapeutically beneficial.
ACVR1 mutations: BMP signalling in DIPGs
The identification of recurrent mutations in the bone morphogenetic protein (BMP) receptor activin receptor type 1 (ACVR1; also known as ALK2) in 46 of 195 (24%) DIPG samples [19] [20] [21] [22] , but not in more than 100 paediatric NBS-HGGs 20, 22, 23 , provides another clear example of unique selective pressures that drive DIPGs. ACVR1-mutant DIPGs have an earlier age of diagnosis and longer overall survival time 21, 22 , occur more frequently in females and frequently also contain histone H3.1 K27M mutations (80%). Given the apparently equivalent consequence of K27M mutations in H3.1 or H3.3 to decrease total cellular levels of H3K27me3, the significant co-occurrence of ACVR1 and HIST1H3B mutations may reflect a specific developmental setting. Surprisingly, some of the same somatic ACVR1 mutations identified in DIPG are found as heterozygous germline mutations that cause the congenital malformation syndrome fibrodysplasia ossificans progressiva (FOP), a disease that is characterized by the formation of heterotopic ossifications in soft tissues at sites of inflammation 82, 83 . FOP is not associated with cancer predisposition, despite the presence of germline mutations that are identical to those found in DIPG. This strongly suggests that ACVR1 mutations do not have a potent tumour-initiating effect in DIPG but rather provide a selective advantage when they are combined with other mutations.
ACVR1 is a type I BMP receptor, which is activated in response to extracellular BMP and in turn phosphorylates and activates downstream growthpromoting genes through SMAD transcription factors (FIG. 5) . Mutations in ACVR1 that are associated with DIPG encode amino acid substitutions in the ATP-binding pocket of the kinase domain or in the adjacent glycine/serine-rich inhibitory domain and would be predicted to result in a shift of the enzyme to the active conformation 84 . Indeed, mutations of these residues induce a weak gain of function, as determined by increased phosphorylation of the downstream substrates SMAD1, SMAD5 or SMAD8 . As in the wild-type setting, interaction of mutant ACVR1 with type II BMP receptors is still required for active signalling 85 . [19] [20] [21] [22] . No mutations were identified in the extracellular (ECD) or transmembrane (TM) domains. All residues targeted are common to those observed in the germlines of patients with fibrodysplasia ossificans progressiva (FOP), with the same amino acid substitutions, except for R258G and G328V, which are, to date, unique to DIPG. b | Bone morphogenetic protein (BMP) signalling pathway. Upon ligand binding, a type 2 receptor, such as BMPR2, heterodimerizes with and phosphorylates (P) ACVR1, a serine/threonine kinase, which in turn phosphorylates the transcription factors SMAD1, SMAD5 or SMAD8, causing binding to SMAD4, translocation to the nucleus, and transcription of target genes such as inhibitor of DNA binding 1 (ID1) and ID2. The ACVR1 mutations in DIPG and FOP enhance the kinase function and/or disrupt the binding of the negative regulator FKBP12 to ACVR1, conferring activation of this pathway.
An activated BMP signalling cascade regulates diverse developmental processes in different tissues. Expression of ACVR1 mutations that are found in DIPG disrupts normal dorsoventral patterning and causes an increased development of ventral structures at the expense of dorsal structures in zebrafish embryos, phenocopying the effects of activated BMP signalling 22, 86 . Overexpression of BMP4 in the brains of transgenic mice induced astrocyte differentiation at the expense of oligodendrocyte formation 87 . Consistent with overactive BMP signalling decreasing the pool of oligodendrocytes, central nervous system (CNS) demyelination was detected in a mouse knock-in model carrying the Acvr1 R206H mutation that is found in both FOP and DIPG, and white matter lesions that might be associated with demyelination were found in a small group of patients with FOP who were evaluated for CNS abnormalities 88 . In adult glioblastoma cancer stem cells, BMP signalling induced differentiation in one study and proliferation in another, depending on epigenetic silencing of BMP receptor type-1B (BMPR1B) 89, 90 . BMP signalling induces differentiation signals and inhibits the tumorigenesis of medulloblastoma, a paediatric brain tumour that arises from granule neuron progenitors 91 . Somatic activating mutations in ACVR1 presumably function as oncogenes in DIPG, probably conferring different downstream cellular responses in this specific context, consistent with different outcomes of BMP signalling during brain development. Indeed, ACVR1 mutations were significantly associated with tumours from younger children, and this suggests a developmental context for this oncogenic signal, even within DIPG.
Conclusions
Overall, paediatric HGGs share histological and clinical features with adult HGGs, as well as mutations in common cancer pathways. However, the recent insights from genome-wide sequencing efforts show that there are unique selective pressures driving tumorigenesis in the developing brain, which vary according to age but also according to anatomical location within the same age group. There is substantial interpatient heterogeneity in the genomic abnormalities between these subgroups, as well as within subgroups. Given the similarities in dismal clinical outcome, it seems that there are multiple genetic and epigenetic mechanisms that drive diffuse HGG, with different mutations converging on shared pathways, as has been observed in the genomic landscapes of many types of cancer 92 . The selection of unique mutations in specific subgroups probably reflects the context-dependent regulation of signalling that varies with developmental setting. These distinctions in disease pathogenesis may indicate that very different therapeutic approaches will be needed to effectively counteract the underlying genetic mutations. The extremely high frequency of histone H3 mutations in DIPG revealed a surprising unifying molecular mechanism driving the disease, and it therefore offers hope that if these mutations could be targeted, effective treatment for this devastating disease could be possible. Although there have been exciting advances in understanding some functional consequences of histone H3 mutations, how these mutations contribute to oncogenesis, and the basis for their regional selectivity remain unclear. Similarly, understanding the oncogenic output of other context-specific mutations, such as aberrant BMP signalling in DIPGs, is crucial. It remains to be determined how therapeutic targeting of paediatric HGG-specific mutations may alter the activity of other signalling pathways in tumour cells or affect non-tumour tissues. Although a paucity of in vitro and in vivo models remains a major limitation in translating these new findings into patient benefit, knowledge of these mutations presents an opportunity for new therapeutic development, as well as novel insights into connections between chromatin regulation, BMP signalling and tumorigenesis.
